MORE►
covid vaccine
TFF Pharmaceuticals CEO Dr. Harlan Weisman [Photo TFF, Background DI Studio]
Fort Worth’s TFF Pharmaceuticals Partners to Develop Dry Powder-Inhaled mRNA Treatment for Flu and COVID
by David Seeley | Sep 13, 2024
Respiratory illnesses like influenza and COVID can change rapidly, requiring the nimble development and delivery of antiviral drugs to combat them. TFF is now partnering with Atlanta's Emory University and the Biomedical Advanced Research and Development Authority (BARDA) to test the feasibility of converting an Emory-developed mRNA antiviral into a dry powder formulation that needs no cold-chain storage.
by Bella Pinera |
Mar 18, 2021
To provide help to those who need the COVID-19 vaccine the most, Shiftsmart is using its tech and wovaccinationrkers to double the throughput of COVID-19 vaccination registrations.
MORE►
by Alex Edwards |
Mar 4, 2021
UNT hopes its cloud-based computer program called RE-PLAN will be able to solve equitable distribution issues that often accompany a speedy rollout. The technology, which uses sourced data to allow public health agencies to craft response plans, will be dispensed with an urgency to target special demographics communities, like people who have disabilities, don't speak English, and don't have cars.
MORE►
by Quincy Preston |
Nov 17, 2020
People under age 50 are "more likely to be hospitalized, need a ventilator, and die from COVID-19 if they're severely obese," a new study says.
MORE►
